PTGX Protagonist Therapeutics Inc.

15.69
-1.76  -10%
Previous Close 17.45
Open 17.41
52 Week Low 4.47
52 Week High 19.67
Market Cap $577,508,859
Shares 36,807,448
Float 36,170,647
Enterprise Value $425,147,913
Volume 1,076,455
Av. Daily Volume 371,261
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
PTG-200
Crohn's disease
Phase 2
Phase 2
Phase 2 ongoing - conducted by Janssen.
PN-943
Ulcerative colitis
Phase 2
Phase 2
Phase 2 trial screening has been initiated - August 6, 2020.
PTG-300
Beta-thalassemia
Phase 2
Phase 2
Phase 2 data presented at EHA June 12, 2020.
PTG-300
Polycythemia vera
Phase 2
Phase 2
Phase 2 initial data released May 7, 2020.
PTG-300
Hereditary hemochromatosis
Phase 2
Phase 2
Phase 2 initiation announced January 6, 2020.
PTG-100
Ulcerative colitis
Phase 2b
Phase 2b
Phase 2b trial discontinued following interim analysis - March 26, 2018. However, company noted August 6, 2018 that human error by CRO contributed to this decision.

Latest News

  1. NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced the appointment of Sarah O'Dowd as an independent director to the Protagonist Board of Directors. Ms. O'Dowd brings broad experience in management and corporate governance to Protagonist, including senior level oversight in the biopharmaceutical industry. In connection with the appointment, Chaitan Khosla, Ph.D., Professor of Chemistry and Engineering at Stanford University, is stepping down from his position on the board.

    "Ms. O'Dowd brings a significant amount of corporate governance, legal and business strategy experience and expertise to the board that will be invaluable with the continued evolution of Protagonist," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. "She has a proven track record of driving growth-oriented strategic plans for public companies, initially as outside corporate counsel and more recently in executive leadership positions. We welcome Sarah to this position as we constantly explore opportunities to build long-term shareholder value through our multiple clinical assets aimed at addressing significant unmet medical needs in hematology/oncology and inflammatory bowel diseases. In addition, we'd like to express our sincere gratitude to Dr. Khosla for his invaluable contributions to the foundation and progression of our research and clinical development functions during his many years with the board and the Company."

    "I am honored to be joining Protagonist board at a critical time of its growth and expansion," commented Ms. O'Dowd. "Protagonist has a compelling pipeline of multiple and well differentiated assets in diverse indications, and I am looking forward to leveraging my experience to benefit Protagonist and support the corporate vision."

    Sarah O'Dowd has been a director of Ichor Holdings since May 2020. Ms. O'Dowd previously served as Senior Vice President, Chief Legal Officer and Secretary at the global technology firm Lam Research Corporation from October 2008 to March 2020. She also served as Lam Research's Vice President of Human Resources from 2009 to 2012. At Lam Research, Ms. O'Dowd led multiple initiatives relating to shareholder outreach on governance, ethics and compliance, IP strategy, foreign trade regulations and M&A transactions. Her experience includes the role of Vice President and General Counsel at FibroGen, a biopharmaceutical company, and a position on the board of directors of Corcept Therapeutics, a pharmaceutical company. Ms. O'Dowd currently serves on the board of directors of the non-profit organization, the Independent Institute, and previously served on the board of trustees of the non-profit organization, the Reason Foundation. Ms. O'Dowd began her career at the law firm Heller Ehrman, where she held responsibility for business strategy. She holds a J.D. from Stanford Law School, an M.A. from Stanford University, and an A.B. from Immaculata College.

    About Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

    Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-appoints-sarah-odowd-to-board-of-directors-301112192.html

    SOURCE Protagonist Therapeutics, Inc.

    View Full Article Hide Full Article
  2. NEWARK, Calif., Aug. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported financial results for the second quarter ended June 30, 2020, and provided an update on clinical development programs.

    "We have succeeded in bringing three differentiated candidates from de novo discovery into Phase 2 development," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. "Each of these candidates has unique attributes that address specific unmet needs in diverse diseases, such as blood disorders with PTG-300 and inflammatory bowel disease with PTG-200 and PN-943. The hepcidin mimetic PTG-300 makes use of the iron homeostasis mechanism of a natural hormone and has demonstrated potential in the treatment…

    NEWARK, Calif., Aug. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported financial results for the second quarter ended June 30, 2020, and provided an update on clinical development programs.

    "We have succeeded in bringing three differentiated candidates from de novo discovery into Phase 2 development," commented Dinesh V. Patel, Ph.D., Protagonist President and Chief Executive Officer. "Each of these candidates has unique attributes that address specific unmet needs in diverse diseases, such as blood disorders with PTG-300 and inflammatory bowel disease with PTG-200 and PN-943. The hepcidin mimetic PTG-300 makes use of the iron homeostasis mechanism of a natural hormone and has demonstrated potential in the treatment of polycythemia vera. We expect to initiate a pivotal study for PTG-300 in 2021 after discussions with the regulatory agencies. PN-943 and PTG-200 are both oral, gut-restricted candidates for the potential treatment of inflammatory bowel disease. PTG-200 is an IL-23 receptor antagonist partnered with Janssen and is currently in a Phase 2 Crohn's study. We recently initiated screening of patients for our Phase 2 study of PN-943 in ulcerative colitis. Finally, we are well financed and recently raised $122 million through a successful secondary offering and use of our ATM program, which enables us to support planned operations through mid-2023."

    Product Development and Corporate Update

    PTG-300: Injectable Hepcidin Mimetic for Polycythemia Vera and Other Blood Disorders

    • Initial Phase 2 results reported in May 2020 in patients with polycythemia vera demonstrated clinically meaningful dose related control of hematocrit levels on individual patient basis.
    • In June 2020, PTG-300 received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of polycythemia vera.
    • Protagonist plans to host a webinar featuring presentations on clinical needs and market research on the potential opportunity for PTG-300 in polycythemia vera. The "PTG-300 Opportunity Update" webinar will be conducted Sept. 11, 2020. Details for participation will be publicly announced prior to the event.

    PN-943: Oral Alpha-4-Beta-7 Integrin Antagonist for Inflammatory Bowel Disease

    • Protagonist has initiated screening of prospective subjects in a global, randomized, double-blind, placebo-controlled Phase 2 study (the "IDEAL Study") evaluating safety, tolerability and efficacy of PN-943 in approximately 150 patients with moderate to severe active ulcerative colitis. Patients will be randomized in one of three arms (150 mg twice daily, 450 mg twice daily, or placebo) for 12 weeks of oral dosing followed by an extended treatment period of 40 weeks. During the extended treatment period all subjects will receive PN-943. The primary endpoint of the study is proportion of subjects achieving clinical remission at week 12 (as defined by rectal bleeding, stool frequency and endoscopic subscores of the Adapted Mayo Score) in the 450 mg twice daily treatment arm as compared to placebo. Secondary endpoints include additional clinical and safety assessments, as well as pharmacokinetic and pharmacodynamic measurements, and biomarker measurements related to disease activity.

    Oral IL-23 Receptor Antagonists (Janssen Biotech and Protagonist Collaboration)

    • Janssen Biotech is conducting a global Phase 2 study of PTG-200 (or JNJ-67864238) in moderate-to-severe Crohn's disease.
    • Joint research efforts are underway to identify second-generation oral IL-23 receptor antagonists for multiple indications.

    Financial Update

    • During May 2020, the Company successfully raised $105.7 million net of underwriting and offering expenses in an oversubscribed secondary offering issuing 8,050,000 shares at $14.00 per share.
    • During the second quarter of 2020, the Company issued 1.2 million shares through its at-the-market (ATM) program and raised $16.8 million, at an average price of $14.02 per share.

    Financial Results

    • Cash, cash equivalents and marketable securities as of June 30, 2020, were $208.7 million. Protagonist estimates sufficient financial resources from its cash, cash equivalents, marketable securities and access to its debt facility to fund its currently planned operating and capital expenditures through mid-2023.
    • License and collaboration revenues were $6.2 million and $9.9 million for the second quarter and six months ended 2020, respectively, in comparison to $(8.2) million and $(6.6) million reported for the same periods of 2019. The increase in revenue was due mainly to the previously reported 2019 one-time cumulative adjustment related to the application of revenue recognition principles following the May 2019 amendment of the Janssen Biotech collaboration agreement that had reduced revenue by $9.4 million for the three and six months ended June 30, 2019.
    • Research and Development ("R&D") expenses for the three and six months ended June 30, 2020, were $20.3 million and $39.0 million, respectively, as compared to $19.4 million and $31.8 million for the same periods of 2019. These variances were primarily due to increased activities in advancing our ongoing clinical trial for polycythemia vera with PTG-300, preparedness for PN-943 Phase 2 study in ulcerative colitis, and our IL-23 receptor antagonist research collaboration activities with Janssen Biotech.
    • General and Administrative ("G&A") expenses for the three and six months ended June 30, 2020, were $4.2 million and $8.8 million, respectively, as compared to $3.9 million and $7.6 million for the same periods of 2019. The increases were primarily due to increases in salaries, insurance expense and professional services to support the growth in our operations.
    • Net loss for the three and six months ended June 30, 2020, was $19.4 million and $39.5 million or a net loss of $0.59 per share and $1.31 per share, respectively, as compared to a net loss of $29.2 million and $43.3 million, or a net loss of $1.18 per share and $1.77 per share, for the same periods of 2019.

    About Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

    Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our ongoing clinical programs, our plans for future clinical trials, the potential of PTG-300 as a possible treatment for polycythemia vera and other blood disorders, the potential of PTG-200 and PN-943 as possible treatments for inflammatory bowel disease, the potential of a pivotal study for PTG-300 in 2021, the potential of our Phase 2 study of PN-943 in ulcerative colitis, the initiation and availability of results of our clinical trials, the sufficiency of our financial resources, our ability to fund our clinical trials, the initiation of and enrollment of patients in our clinical trials, the results of clinical trials and the outlook for our other programs. In some cases, you can identify these statements by forward-looking words such as "potential," "expect," "plan," "estimate," "will," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen Biotech, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates and risks related to the global COVID-19 pandemic and actions taken to slow its spread.  Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

    PROTAGONIST THERAPEUTICS, INC.

    Selected Consolidated Balance Sheet Data

    (In thousands)

    (Unaudited)





    June 30, 2020



    December 31, 2019

    Cash, cash equivalents and marketable securities

    $

    208,665





    $

    133,017



    Working capital

    182,106





    109,905



    Total assets

    224,980





    154,917



    Long-term debt, net

    --





    9,794



    Deferred revenue - related party

    34,014





    41,530



    Accumulated deficit

    (257,162)





    (217,661)



    Total stockholders' equity

    167,485





    79,964



     

    PROTAGONIST THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (Amounts in thousands except share and per share data)

    (unaudited)





    Three Months Ended June 30,



    Six Months Ended June 30,



    2020



    2019



    2020



    2019

    Revenue:















    License and collaboration revenue - related party

    $

    6,217





    $

    (8,189)





    $

    9,864





    $

    (6,629)



    Operating expenses:















    Research and development (1)

    20,257





    19,355





    39,025





    31,799



    General and administrative (1)

    4,177





    3,863





    8,753





    7,627



    Total operating expenses

    24,434





    23,218





    47,778





    39,426



    Loss from operations

    (18,217)





    (31,407)





    (37,914)





    (46,055)



    Interest income

    207





    641





    733





    1,372



    Interest expense

    (209)





    --





    (452)





    --



    Loss on early repayment of debt

    (585)





    --





    (585)





    --



    Other income (expense), net

    512





    (37)





    22





    (39)



    Loss before income taxes

    (18,292)





    (30,803)





    (38,196)





    (44,722)



    Income tax (expense) benefit

    (1,129)





    1,629





    (1,305)





    1,445



    Net loss

    $

    (19,421)





    $

    (29,174)





    $

    (39,501)





    $

    (43,277)



    Net loss per common share, basic and diluted

    $

    (0.59)





    $

    (1.18)





    $

    (1.31)





    $

    (1.77)



    Weighted-average shares used to compute net loss per share,

    basic and diluted



    32,799,691







    24,662,779





    30,251,805





    24,481,186



















    (1)Amounts include non-cash stock-based compensation

    expense as follows (in thousands):

     































    Stock-based compensation

    Three Months Ended June 30,



    Six Months Ended June 30,



    2020



    2019



    2020



    2019

    Research and development

    $

    1,026





    $

    977





    $

    2,092





    $

    2,100



    General and administrative

    970





    1,036





    1,952





    1,892



    Total stock-based compensation expense

    $

    1,996





    $

    2,013





    $

    4,044





    $

    3,992



     

    Cision View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-second-quarter-financial-results-and-provides-corporate-update-301107932.html

    SOURCE Protagonist Therapeutics, Inc.

    View Full Article Hide Full Article
  3. NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis.

    "Receiving FDA orphan drug designation is another important milestone for Protagonist and underscores the importance of our work in polycythemia vera," commented Samuel Saks, M.D., Protagonist Chief Medical Officer. "Individuals living with polycythemia vera face a high disease burden. PTG-300 has a non-cytoreductive…

    NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis.

    "Receiving FDA orphan drug designation is another important milestone for Protagonist and underscores the importance of our work in polycythemia vera," commented Samuel Saks, M.D., Protagonist Chief Medical Officer. "Individuals living with polycythemia vera face a high disease burden. PTG-300 has a non-cytoreductive therapeutic mechanism in the treatment of polycythemia vera and has shown a well-tolerated safety profile to date. Because of its properties, PTG-300 may help provide sustained control of hematocrit and potentially help address symptoms of polycythemia vera and systemic iron deficiency in these patients."

    Protagonist recently announced initial Phase 2 results in patients with polycythemia vera that demonstrated robust clinical response and clinically meaningful dose related control of hematocrit levels on individual patient basis.

    About Polycythemia Vera

    Polycythemia vera is a myeloproliferative neoplasm characterized primarily by the increased production of red blood cells. Well-established treatment guidelines focus on maintaining hematocrit levels below 45 percent to reduce the risk of thrombotic events. Unfortunately, current treatment options are unable to maintain hematocrit to below the 45 percent target for many patients. In addition, current options are intolerable to some patients and may be associated with serious side effects, such as exacerbation of iron deficiency with phlebotomy. There are an estimated 100,000 patients with polycythemia vera in the U.S. and approximately 100,000 patients in major EU countries. Patients are classified as either low risk or high risk based on prior thrombotic events and age. A treatment option that could provide consistent control of hematocrit over time without fluctuations above 45 percent could be an important component of care for both low and high risk polycythemia vera patient populations.

    About Orphan Drug Designation

    The FDA grants Orphan Drug Designation to novel drugs or biologics that treat rare diseases or conditions affecting fewer than 200,000 patients in the U.S. The designation allows the sponsor of the drug to be eligible for a seven-year period of U.S. marketing exclusivity on approval of the drug, as well as tax credits for clinical research costs, the ability to apply for annual grant funding, clinical trial design assistance, and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees.

    About Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

    Protagonist is headquartered in Newark, California. For further information, please visit www.protagonist-inc.com

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our clinical programs, the potential of PTG-300 as a possible treatment for polycythemia vera and hereditary hemochromatosis, the safety profile of PTG-300, the potential for PTG-300 to provide sustained control of hematocrit in patients, the potential for PTG-300 to help address symptoms of polycythemia vera and systemic iron deficiency in patients, the results of the Phase 2 study of PTG-300 in polycythemia vera and the results of future studies for the treatment of polycythemia vera. In some cases, you can identify these statements by forward-looking words such as "may," "potential," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates and risks related to the global COVID-19 pandemic and actions taken to slow its spread. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our Quarterly Report on Form 10-Q for the period ended March 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

     

    Cision View original content:http://www.prnewswire.com/news-releases/hepcidin-mimetic-ptg-300-receives-us-fda-orphan-drug-designation-for-the-treatment-of-polycythemia-vera-301079240.html

    SOURCE Protagonist Therapeutics, Inc.

    View Full Article Hide Full Article
  4. NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association (EHA) Annual Congress, which will take place in a virtual format June 11-14, 2020. Details of the oral presentation are as follows:

    Presentation Title: A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects
    Session: New therapeutic approaches for thalassemia
    Abstract: S298
    Date and Time: Available on the on-demand Virtual Congress platform on Friday, June 12, 2020, at 8:30 a.m. CEST

    Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

    About

    NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association (EHA) Annual Congress, which will take place in a virtual format June 11-14, 2020. Details of the oral presentation are as follows:

    Presentation Title: A hepcidin mimetic, PTG-300, demonstrates pharmacodynamic effects indicating reduced iron availability in transfusion-dependent beta-thalassemia subjects
    Session: New therapeutic approaches for thalassemia
    Abstract: S298
    Date and Time: Available on the on-demand Virtual Congress platform on Friday, June 12, 2020, at 8:30 a.m. CEST

    Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

    About Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

    Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-25th-european-hematology-association-eha-annual-congress-301070262.html

    SOURCE Protagonist Therapeutics, Inc.

    View Full Article Hide Full Article
  5. NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming virtual healthcare investor conferences.

    Presentation details:
    Event: Jefferies Virtual Healthcare Conference
    Date: Wednesday, June 3, 2020
    Time: 10:30 a.m. EDT

    Event: Raymond James Human Health Innovations Conference
    Date: Thursday, June 18, 2020                      
    Time: 1:40 p.m. EDT

    Live and archived webcasts of the Jefferies and Raymond James presentations can be accessed by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

    About Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. The Company currently has three clinical-stage assets. PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in development for the treatment of inflammatory bowel disease, with Crohn's disease as the initial indication. The Company has a worldwide license and collaboration agreement with Janssen Biotech, Inc., for the development of PTG-200. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in development for the treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication.

    Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

     

    Cision View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-two-upcoming-healthcare-investor-conferences-301066740.html

    SOURCE Protagonist Therapeutics, Inc.

    View Full Article Hide Full Article
View All Protagonist Therapeutics Inc. News